Effectiveness and Safety of Venlafaxine in Japanese Major Depressive Disorder Patients with or without Anxious Distress (EXPAND Study): A 12-Week Prospective Observational Study Authors: Hitoshi Sakurai, Keisuke Nomoto, Tomoki Ito, Yasuyuki Matsumoto, Shingo Higa Published: 2026 ABSTRACT PurposeThis study evaluated outcomes of venlafaxine treatment in Japanese patients with major depressive disorder (MDD) in routine clinical practice. Since anxiety is a common and clinically relevant feature of MDD, descriptive analyses were conducted based on the presence or absence of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) anxious distress.Patients and MethodsThis 12-week, multicenter, single-arm, observational study consecutively enrolled adult patients with MDD initiating venlafaxine in Japan. DSM-5 anxious distress was assessed at baseline. The primary endpoint was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 12 or discontinuation. Secondary endpoints included MADRS response and remission rates, patient-reported outcomes, and safety. Analyses were descriptive and conducted by anxious distress status.ResultsAmong enrolled patients, 407 received venlafaxine and comprised the safety analysis set; 198 (48.6%) had anxious distress. MADRS total score decreased from baseline to week 12 or discontinuation in the overall population and in patients with and without anxious distress. Patients with anxious distress had higher baseline symptom severity but showed improvement over time. Similar improvements were seen across secondary patient-reported outcomes in both subgroups. Drug-related adverse events and discontinuations due to adverse events were numerically more frequent in patients with anxious distress. The safety profile was in line with established findings.ConclusionVenlafaxine treatment in clinical practice improved depressive symptoms, anxiety, functioning, quality of life, and cognitive complaints in patients with MDD. Improvements were seen in patients with and without anxious distress. These results provide descriptive real-world evidence on treatment outcomes; however, they should be interpreted with caution given the non-comparative study design and other limitations. The findings may inform clinical decision-making in patients with heterogeneous presentations encountered in routine psychiatric practice. Introduction Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders worldwide, affecting hundreds of millions of individuals, and is characterized by persistent depressed mood, diminished interest or pleasure in activities, recurrent thoughts of death, and various physical and cognitive symptoms.1,2 In addition to core depressive symptoms, anxiety symptoms are highly prevalent in patients with MDD and have long been recognized as an important clinical factor associated with poorer clinical status and greater functional impairment.3,4 Historically, anxiety in MDD has been primarily characterized by using dimensional rating scales, such as the anxiety/somatization factor of the Hamilton Depression Rating Scale (HAM-D). Studies have shown that patients with so-called “anxious depression” defined using such scales, exhibit less favorable treatment outcomes, including lower remission rates and reduced treatment response compared with patients without prominent anxiety symptoms.5,6 These prior studies have often relied on rating scale-based definitions to characterize anxiety in MDD, which may contribute to differences in how anxious depression is defined across studies. In addition, clinically meaningful anxiety symptoms are frequently observed in patients who do not meet full diagnostic criteria for comorbid anxiety disorders such as generalized anxiety disorder (GAD), suggesting that categorical comorbidity alone may not fully capture the spectrum of anxiety presentations in MDD.7,8 To address these challenges, the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition9 (DSM-5, currently DSM-5 Text Revision),10 released in 2013, introduced the “anxious distress” specifier, as part of the diagnostic evaluation of MDD. This specifier provides a clinically meaningful and standardized framework for characterizing anxiety symptoms within depressive episodes and is defined by the presence of at least 2 of the following 5 anxiety symptoms: feeling keyed up or tense, feeling unusually restless, difficulty concentrating due to worry, fear that something awful may happen, and feeling loss of control.3,11 Subsequent studies have demonstrated that the DSM-5 anxious distress specifier is common—occurring in approximately 50–75% of patients with MDD—and is associated with greater symptom severity, functional impairment, and poorer longitudinal outcomes.4,7,8,11–13 Furthermore, emerging evidence indicates that anxious distress may provide prognostic information beyond that captured by comorbid anxiety disorders.7,13 Although the DSM-5 anxious distress specifier overlaps clinically with broader constructs such as “anxious depression” or anxiety symptoms in MDD used in earlier studies, they are not identical. Previous studies often defined anxious depression based on dimensional rating scales such as HAM-D or Hamilton Anxiety Rating Scale (HAM-A), which are widely used to quantify the severity of anxiety symptoms, but they are not incorporated into diagnostic systems. Whereas the DSM-5 anxious distress specifier provides a simpler, clinically standardized approach to categorizing anxiety symptoms within the diagnostic framework of MDD. Management of MDD typically includes pharmacological and psychotherapeutic interventions, supplemented by lifestyle modification. Current treatment guidelines issued by the Japanese Society of Mood Disorders, the American Psychiatric Association, and the Canadian Network for Mood and Anxiety Treatments recommend antidepressants as first-line therapy for patients with moderate-to-severe MDD.14–16 Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is approved globally in its extended-release formulation (Effexor XR®) for the treatment of adult MDD, GAD, social anxiety disorder, and panic disorder. In Japan, venlafaxine sustained release (Effexor® SR; Viatris Pharmaceuticals Japan G.K., Tokyo, Japan) is approved for depression or depressive states. Following a Phase 3 trial in Japan demonstrating its efficacy and tolerability,17 venlafaxine was approved for an additional indication of GAD in March 2026. Although clinical studies have shown that venlafaxine is effective in patients with MDD accompanied by anxiety symptoms,18–20 these studies have primarily relied on anxiety rating scales of HAM-D or HAM-A, rather than the DSM-5 anxious distress specifier. To date, prospective real-world data specifically examining venlafaxine treatment outcomes in patients classified according to DSM-5 anxious distress status remain relatively limited, particularly in Japanese clinical settings. In addition, most studies using the DSM-5 anxious distress specifier have been conducted in Western populations and have discussed differences in clinical characteristics and treatment responses as well as patients’ social background between groups, suggesting the importance of evaluating antidepressant outcomes in diverse clinical settings. Therefore, the objective of the present prospective, single-arm observational study was to evaluate the effectiveness and safety of venlafaxine in Japanese patients with MDD and to descriptively examine clinical outcomes in patients with and without anxious distress in a real-world clinical setting. Material and Methods Study Design This was a prospective, multicenter, single-arm, observational study (the EXPAND study) conducted at 22 sites across Japan. Patients with MDD were enrolled consecutively according to eligibility criteria during routine clinical practice at participating sites. Anxious distress was evaluated by investigators at baseline according to the DSM-5 anxious distress specifier. At the time of statistical analysis, patients were classified into 2 subgroups: those with anxious distress, defined as having at least 2 of the 5 anxious distress symptoms, and those without anxious distress. The observation duration was 12 weeks. Patients who enrolled during the registration period and received venlafaxine as part of routine clinical practice were assessed at baseline and at study visits at weeks 4, 8, and 12 following treatment initiation. Data were collected at each site by investigators using standardized assessment procedures through patient interviews. This study was conducted from May 2024 through July 2025 and was registered in the Japan Registry of Clinical Trials in February 2024 (jRCT1031230620). This observational study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, and the STROBE checklist was used when reporting. Ethical Considerations The study was approved on 17 January 2024 (approval number: QTN09945) by the Medical Corporation TOUKEIKAI Kitamachi Clinic Ethics Review Board, an ethics committee established at Medical Corporation TOUKEIKAI Kitamachi Clinic, Tokyo, Japan, which served as the central ethics committee for this study. Written informed consent was obtained from all participants before any study-related procedures, including screening assessments. This study was conducted in accordance with Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology, Declaration of Helsinki and its amendments, and the applicable Japanese Ethical Guidelines for Life Science and Medical Research Involving Human Subjects. Participants Eligible participants were Japanese outpatients aged 18 years or older who had a primary diagnosis of MDD according to DSM-5 criteria, with either single or recurrent episodes, and without psychotic or mixed features. All participants were required to have a Clinical Global Impression-Severity (CGI-S) score of 4 or higher at baseline, as assessed for this study by an experienced investigating psychiatrist at each site. Patients were excluded if they had prior treatment with venlafaxine or desvenlafaxine. Additional exclusion criteria included a DSM-5 diagnosis of alcohol or substance use disorder (excluding nicotine or caffeine) within 12 months before study entry; a current or past diagnosis of schizophrenia spectrum or other psychotic disorders; or a current or past diagnosis of bipolar and related disorders. Patients with a history of convulsive disease other than a single febrile seizure in childhood were excluded, as were those with dementia or other neurodegenerative conditions significantly affecting cognitive function. Depression secondary to another medical condition or to substance use was also an exclusion criterion. Patients receiving, or scheduled to receive, electroconvulsive therapy or repetitive transcranial magnetic stimulation within 12 weeks were excluded. Individuals with serious or unstable medical conditions, such as severe renal or hepatic dysfunction, or those judged by the investigator to be at risk of imminent suicide based on their medical history and current condition, were not eligible. Assessments Efficacy and safety were evaluated at baseline and at weeks 4, 8, and 12. The primary endpoint was the change from baseline to treatment completion (week 12) or discontinuation in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.21 The structured interview guide for MADRS (SIGMA) was used.22 Total score ranges from 0 to 60, with higher scores indicating more severe depression, as assessed by the investigator. MADRS interviews were conducted by qualified psychiatrists, clinical psychologists, as well as licensed psychologists, or nurses with experience in MADRS assessments in clinical trials. Training on the use of the SIGMA structured interview guide was required for licensed psychologists and nurses. To minimize intra-patient variability, investigators were requested to have the same evaluator perform longitudinal assessments for each patient whenever possible. Inter-rater reliability was not formally assessed. Secondary endpoints included changes from baseline in validated measures of symptoms, quality of life (QOL), and functional impairment. Patient-reported outcomes were collected using the Japanese versions of the following instruments: the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) for depressive symptoms,23 Generalized Anxiety Disorder 7-item (GAD-7) for anxious symptoms,24,25 Sheehan Disability Scale (SDS) for functioning,26 EuroQol 5 dimensions 5-level (EQ-5D-5L) for health-related QOL,27 and the Perceived Deficits Questionnaire for Depression 5-item (PDQ-D-5) for cognitive symptoms.28 When patients required assistance in using patient-reported outcomes due to literacy or other practical difficulties, support was provided by clinical research coordinators or site staff, while ensuring that responses reflected the patient’s own perceptions. Additional secondary endpoints included the response rate (defined as a ≥50% reduction from baseline in the MADRS total score) and the remission rate (defined as a MADRS total score ≤10). Safety was assessed throughout the treatment period by monitoring adverse events, adverse events leading to discontinuation of venlafaxine, and serious adverse events resulting in death. The causal relationship of each adverse event to venlafaxine was assessed by the investigator. Statistical Analysis Demographic and baseline characteristics were summarized for the overall population and by DSM-5 anxious distress status. The primary endpoint was defined as the change from baseline to the last available MADRS total score at week 12 or at an earlier scheduled assessment (week 4 or week 8, whichever occurred later) in cases of premature discontinuation, based on an observed case approach without imputation. Comparisons between patients with and without anxious distress were not a primary objective of the study. Efficacy analyses included summary statistics for each assessment score and for changes from baseline at each visit, and within‑group changes from baseline were evaluated using the paired t test. Response and remission in MADRS total score were summarized as proportions. For safety analyses, treatment‑emergent adverse events (TEAEs), defined as events occurring from the first dose through 30 days after the last dose, were summarized as counts and percentages. In this study, formal diagnoses of comorbid anxiety disorders (eg, GAD, panic disorder, or social anxiety disorder) were not systematically assessed, and no adjustments for such comorbidities were included in the analyses. All analyses were conducted using observed cases only; no imputation was performed for missing data. Safety was evaluated in the safety analysis set, which comprised all patients who received at least one dose of venlafaxine. The full analysis set was the primary population for efficacy analyses and included all patients who were treated with venlafaxine and had available MADRS total scores at baseline and at least one postbaseline assessment. To assess the consistency of observed results, analyses were also conducted in the per‑protocol set, which included patients in the full analysis set who completed the final visit at week 12 without any protocol violations. In addition, to assess effectiveness in the population who were administered venlafaxine according to the prespecified dose and titration scheme, an exploratory analysis set was defined as patients in the full analysis set who did not meet any of the following administration and dose exclusion criteria: an initial dose greater than 37.5 mg/day; a maximum dose greater than 225 mg/day; a dose of less than 75 mg/day at or after the week‑4 visit; a dose‑escalation pattern other than 37.5 mg/day to 75 mg/day, 75 mg/day to 150 mg/day, or 150 mg/day to 225 mg/day; or a dose increase occurring less than one week after the previous dose. Results Patient Disposition and Analysis Sets Patient disposition and reasons for exclusion are summarized in Figure 1. A total of 420 patients provided informed consent, of whom 410 were enrolled, and all but three patients subsequently received at least one dose of venlafaxine. The safety analysis set comprised 407 patients, including 198 (48.6%) patients with anxious distress and 209 (51.4%) without anxious distress. After exclusion of patients without evaluable baseline or postbaseline MADRS assessments, 381 patients (183 with anxious distress and 198 without anxious distress) were included in the full analysis set. Of the full analysis set, 37 patients (19 with anxious distress and 18 without) were not included in the per-protocol set. The per-protocol set included patients who completed the final visit at week 12 without any protocol violations (344 patients; 164 with anxious distress and 180 without). Figure 1Patients disposition.The flowchart outlines patient disposition in a study. Initially, 420 patients consented to participate, with 10 deemed ineligible, leaving 410 enrolled. Three were excluded for not receiving venlafaxine, resulting in a safety analysis set of 407 patients, split into 198 with anxious distress and 209 without. Twenty-six were excluded for not obtaining MADRS scores, leaving a full analysis set of 381 patients, with 183 having anxious distress and 198 without. The exploratory analysis set included 277 patients, with 123 having anxious distress and 154 without. Exclusions from the full analysis set included 104 patients for dosage issues: initial dosage over 37.5mg/day (2), dosage under 75mg/day after week-4 visit (73), non-standard dose increase patterns (21) and dose increase within a week of the last dose (15). After 37 patients were excluded from the full analysis set for not completing the week-12 visit, the resulting per-protocol set comprised 344 patients, with 164 having anxious distress and 180 without.A flowchart of patient disposition in a study with analysis sets and reasons for exclusion.Notes: The full analysis set (primary population for efficacy evaluation) included all patients who received venlafaxine and had MADRS total scores at baseline and at least one postbaseline assessment. The per‑protocol set consisted of patients in the full analysis set who completed the week-12 visit without any protocol violations. The exploratory analysis set consisted of patients in the full analysis set who received venlafaxine according to the prespecified dose and titration scheme as outlined in the package insert.Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; n, number of subjects within each category. Patients disposition. Baseline Demographic and Clinical Characteristics Of the 198 patients who had anxious distress, 92 (46.5%), 61 (30.8%), and 45 (22.7%) were diagnosed as mild, moderate, and moderate to severe or more, respectively (Table 1). Patients with anxious distress were younger than those without anxious distress. The proportion of living with cohabitants was higher among patients without anxious distress than among those with anxious distress. Baseline depressive symptom severity, as assessed by MADRS and GAD-7, was higher in patients with anxious distress, whereas other demographic and clinical characteristics were generally similar between groups.Table 1Baseline Demographic and Clinical Characteristics of the PatientsVariablesOverall (N=407)With Anxious Distress (N=198)Without Anxious Distress (N=209)P-ValueAge (years)Mean ± SD43.0 ± 14.041.0 ± 13.244.9 ± 14.40.005Femalen (%)253 (62.2)129 (65.2)124 (59.3)0.261Education (years)Mean ± SD13.7 ± 2.413.7 ± 2.513.7 ± 2.40.782Marriedn (%)136 (33.4)73 (36.9)63 (30.1)0.065Living with cohabitants: yesn (%)273 (67.1)153 (77.3)120 (57.4)<0.001MDD diagnosis (DSM-5) Single episoden (%)169 (41.5)79 (39.9)90 (43.1)0.546 Duration of current episode (months)Mean ± SD13.3 ± 30.015.2 ± 34.511.4 ± 24.90.211DSM-5 anxious distress Non (%)209 (51.4)0209 (100)<0.001 Mildn (%)92 (22.6)92 (46.5)0 Moderaten (%)61 (15.0)61 (30.8)0 Moderate to severe or moren (%)45 (11.1)45 (22.7)0Baseline score of scales MADRS total scoreMean ± SD27.6 ± 7.129.3 ± 6.825.9 ± 7.0<0.001 QIDS-SR total scoreMean ± SD15.4 ± 5.015.9 ± 4.814.9 ± 5.10.065 GAD-7 total scoreMean ± SD10.4 ± 5.011.6 ± 4.89.2 ± 5.0<0.001 SDS total scoreMean ± SD17.6 ± 7.518.1 ± 7.517.1 ± 7.40.177 EQ-5D-5L QOL scoreMean ± SD0.62 ± 0.180.61 ± 0.180.64 ± 0.180.054 PDQ-D-5 total scoreMean ± SD14.1 ± 5.014.6 ± 5.313.7 ± 4.70.061Notes: Percentages (%) are based on the number of patients in the safety analysis set in each group (N). P-values of the difference between patients with and without anxious distress were calculated using t test for continuous variables or Fisher’s exact test for categorical variables.Abbreviations: DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; EQ-5D-5L, EuroQol 5 dimensions 5-level; GAD-7, Generalized Anxiety Disorder 7-item; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; n, number of subjects within each category; PDQ-D-5, Perceived Deficits Questionnaire for Depression 5-item; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; QOL, quality of life; SD; standard deviation; SDS, Sheehan Disability Scale. Table 1Baseline Demographic and Clinical Characteristics of the PatientsVariablesOverall (N=407)With Anxious Distress (N=198)Without Anxious Distress (N=209)P-ValueAge (years)Mean ± SD43.0 ± 14.041.0 ± 13.244.9 ± 14.40.005Femalen (%)253 (62.2)129 (65.2)124 (59.3)0.261Education (years)Mean ± SD13.7 ± 2.413.7 ± 2.513.7 ± 2.40.782Marriedn (%)136 (33.4)73 (36.9)63 (30.1)0.065Living with cohabitants: yesn (%)273 (67.1)153 (77.3)120 (57.4)<0.001MDD diagnosis (DSM-5) Single episoden (%)169 (41.5)79 (39.9)90 (43.1)0.546 Duration of current episode (months)Mean ± SD13.3 ± 30.015.2 ± 34.511.4 ± 24.90.211DSM-5 anxious distress Non (%)209 (51.4)0209 (100)<0.001 Mildn (%)92 (22.6)92 (46.5)0 Moderaten (%)61 (15.0)61 (30.8)0 Moderate to severe or moren (%)45 (11.1)45 (22.7)0Baseline score of scales MADRS total scoreMean ± SD27.6 ± 7.129.3 ± 6.825.9 ± 7.0<0.001 QIDS-SR total scoreMean ± SD15.4 ± 5.015.9 ± 4.814.9 ± 5.10.065 GAD-7 total scoreMean ± SD10.4 ± 5.011.6 ± 4.89.2 ± 5.0<0.001 SDS total scoreMean ± SD17.6 ± 7.518.1 ± 7.517.1 ± 7.40.177 EQ-5D-5L QOL scoreMean ± SD0.62 ± 0.180.61 ± 0.180.64 ± 0.180.054 PDQ-D-5 total scoreMean ± SD14.1 ± 5.014.6 ± 5.313.7 ± 4.70.061Notes: Percentages (%) are based on the number of patients in the safety analysis set in each group (N). P-values of the difference between patients with and without anxious distress were calculated using t test for continuous variables or Fisher’s exact test for categorical variables.Abbreviations: DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; EQ-5D-5L, EuroQol 5 dimensions 5-level; GAD-7, Generalized Anxiety Disorder 7-item; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; n, number of subjects within each category; PDQ-D-5, Perceived Deficits Questionnaire for Depression 5-item; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; QOL, quality of life; SD; standard deviation; SDS, Sheehan Disability Scale. Baseline Demographic and Clinical Characteristics of the Patients Notes: Percentages (%) are based on the number of patients in the safety analysis set in each group (N). P-values of the difference between patients with and without anxious distress were calculated using t test for continuous variables or Fisher’s exact test for categorical variables. Abbreviations: DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; EQ-5D-5L, EuroQol 5 dimensions 5-level; GAD-7, Generalized Anxiety Disorder 7-item; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; n, number of subjects within each category; PDQ-D-5, Perceived Deficits Questionnaire for Depression 5-item; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; QOL, quality of life; SD; standard deviation; SDS, Sheehan Disability Scale. Primary Efficacy Outcome: Change in MADRS Total Score Among patients in the full analysis set, 370 patients (177 with anxious distress and 193 without anxious distress) had at least one postbaseline MADRS assessment at week 4, 8, or 12 and were included in the primary endpoint analysis. Of these, 315 patients (154 with anxious distress and 161 without) had MADRS assessments at week 12, while 55 patients (23 with anxious distress and 32 without) had assessments only at earlier scheduled timepoints (week 4 or week 8). A total of 11 patients (6 with anxious distress and 5 without) who had postbaseline MADRS assessment only at unscheduled timepoints were excluded from the analysis. Across the overall population, mean MADRS total scores decreased significantly from baseline (27.6 ± 7.2) to week 12 or discontinuation (14.9 ± 10.3), yielding a mean change of −12.7 ± 11.2 (P<0.001) (Table 2). Improvements were observed in both patients with anxious distress (mean change, −13.3 ± 11.1; P<0.001) and those without anxious distress (mean change, −12.1 ± 11.2; P<0.001).Table 2Changes from Baseline in MADRS Total Scores at Treatment Completion (Week 12) or DiscontinuationMADRS Total ScoreOverall (N=381)With Anxious Distress (N=183)Without Anxious Distress (N=198)Baselinen381183198Mean ± SD27.6 ± 7.229.4 ± 6.925.9 ± 7.0Treatment completion (week 12) or Discontinuationn370177193Mean ± SD14.9 ± 10.316.1 ± 10.713.8 ± 9.8Change from baselineMean ± SD−12.7 ± 11.2−13.3 ± 11.1−12.1 ± 11.2P-value<0.001<0.001<0.001Notes: N denotes the number of patients in the full analysis set in each group. P-values of the change from baseline were calculated using the paired t test.Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; n, number of subjects within each category; SD; standard deviation. Table 2Changes from Baseline in MADRS Total Scores at Treatment Completion (Week 12) or DiscontinuationMADRS Total ScoreOverall (N=381)With Anxious Distress (N=183)Without Anxious Distress (N=198)Baselinen381183198Mean ± SD27.6 ± 7.229.4 ± 6.925.9 ± 7.0Treatment completion (week 12) or Discontinuationn370177193Mean ± SD14.9 ± 10.316.1 ± 10.713.8 ± 9.8Change from baselineMean ± SD−12.7 ± 11.2−13.3 ± 11.1−12.1 ± 11.2P-value<0.001<0.001<0.001Notes: N denotes the number of patients in the full analysis set in each group. P-values of the change from baseline were calculated using the paired t test.Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; n, number of subjects within each category; SD; standard deviation. Changes from Baseline in MADRS Total Scores at Treatment Completion (Week 12) or Discontinuation Notes: N denotes the number of patients in the full analysis set in each group. P-values of the change from baseline were calculated using the paired t test. Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; n, number of subjects within each category; SD; standard deviation. Secondary Efficacy Outcome: MADRS Score Over Time Mean MADRS total scores showed broadly similar patterns of change over time in both subgroups, with progressive reductions at weeks 4, 8, and 12 (Figure 2 and Table S1 in the Supplementary Materials); no formal statistical comparisons between subgroups were performed. At week 12, MADRS total scores were reduced compared with baseline in both subgroups. Figure 2Mean MADRS total score at baseline and weeks 4, 8, and 12.Line chart of mean MADRS total scores with three colored series (overall population, with anxious distress, without anxious distress) and vertical error bars at four time points: baseline, week 4, week 8 and week 12. The y-axis runs from 0 to 40 and represents a MADRS (depression symptom) total score. All three lines slope downward across visits, indicating improvement over time; the anxious-distress group starts highest and remains slightly higher than the without anxious-distress group at each follow-up. A table beneath the plot provides mean plus or minus standard deviation and sample size for each group at each time point: Overall 27.6 plus or minus 7.2 (n=381), 20.2 plus or minus 8.6 (n=352), 16.2 plus or minus 9.9 (n=322), 13.9 plus or minus 10.0 (n=315); With anxious distress 29.4 plus or minus 6.9 (n=183), 21.2 plus or minus 8.9 (n=171), 16.8 plus or minus 10.3 (n=151), 14.9 plus or minus 10.5 (n=154); Without anxious distress 25.9 plus or minus 7.0 (n=198), 19.2 plus or minus 8.3 (n=181), 15.6 plus or minus 9.4 (n=171), 13.0 plus or minus 9.4 (n=161).Three-group trend chart with error bars showing MADRS total scores dropping from baseline to week 12.Notes: Mean MADRS total scores over time are presented for the overall population (blue), patients with anxious distress (red), and patients without anxious distress (green). Error bars represent SDs. N denotes the number of patients in the full analysis set in each group.Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; n, number of subjects within each category; SD; standard deviation. Mean MADRS total score at baseline and weeks 4, 8, and 12. A total of 66 patients (29 with anxious distress and 37 without anxious distress) did not have a week-12 MADRS assessment. The most common reason for missing data was discontinuation due to adverse events (26 patients; 15 with anxious distress and 11 without). Secondary Patient-Reported Outcomes Changes from baseline in secondary patient-reported outcomes, including QIDS-SR, GAD-7, SDS, EQ-5D-5L, and PDQ-D-5 scores, showed statistically significant improvements at week 12 in the overall population (Table 3), with data for all timepoints provided in Table S2 in the Supplementary Materials.Table 3Changes from Baseline in Patient-Reported Outcomes at Baseline and Week 12InstrumentGroupVisitScoresChange from BaselinenMean ± SDnMean ± SDP-ValueQIDS-SR total scoreOverallBaseline38115.5 ± 5.0–––Week 123159.5 ± 5.7315−6.0 ± 5.9<0.001With anxious distressBaseline18316.0 ± 4.9–––Week 121549.5 ± 5.8154−6.3 ± 6.2<0.001Without anxious distressBaseline19815.0 ± 5.1–––Week 121619.5 ± 5.7161−5.7 ± 5.7<0.001GAD-7 total scoreOverallBaseline38110.4 ± 5.1–––Week 123155.8 ± 5.0315−4.5 ± 5.5<0.001With anxious distressBaseline18311.6 ± 4.8–––Week 121546.1 ± 5.0154−5.3 ± 5.8<0.001Without anxious distressBaseline1989.2 ± 5.0–––Week 121615.6 ± 4.9161−3.7 ± 5.2<0.001SDS total scoreOverallBaseline37217.7 ± 7.5–––Week 1231511.3 ± 8.7309−6.5 ± 9.3<0.001With anxious distressBaseline18118.3 ± 7.6–––Week 1215411.8 ± 8.8152−6.2 ± 9.2<0.001Without anxious distressBaseline19117.1 ± 7.4–––Week 1216110.9 ± 8.6157−6.7 ± 9.6<0.001EQ-5D-5L QOL scoreOverallBaseline3810.62 ± 0.18–––Week 123140.74 ± 0.193140.11 ± 0.19<0.001With anxious distressBaseline1830.61 ± 0.18–––Week 121540.74 ± 0.201540.13 ± 0.19<0.001Without anxious distressBaseline1980.64 ± 0.18–––Week 121600.74 ± 0.181600.10 ± 0.18<0.001PDQ-D-5 total scoreOverallBaseline37914.1 ± 5.0–––Week 1231311.5 ± 5.1312−2.9 ± 4.7<0.001With anxious distressBaseline18314.6 ± 5.3–––Week 1215411.8 ± 5.2154−2.9 ± 4.6<0.001Without anxious distressBaseline19613.7 ± 4.7–––Week 1215911.3 ± 5.0158−2.8 ± 4.8<0.001Notes: Analyses were based on the full analysis set. P-values of the change from baseline were calculated using the paired t test.Abbreviations: EQ-5D-5L, EuroQol 5 dimensions 5-level; GAD-7, Generalized Anxiety Disorder 7-item; n, number of subjects within each category; PDQ-D-5, Perceived Deficits Questionnaire for Depression 5-item; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; QOL, quality of life; SD; standard deviation; SDS, Sheehan Disability Scale. Table 3Changes from Baseline in Patient-Reported Outcomes at Baseline and Week 12InstrumentGroupVisitScoresChange from BaselinenMean ± SDnMean ± SDP-ValueQIDS-SR total scoreOverallBaseline38115.5 ± 5.0–––Week 123159.5 ± 5.7315−6.0 ± 5.9<0.001With anxious distressBaseline18316.0 ± 4.9–––Week 121549.5 ± 5.8154−6.3 ± 6.2<0.001Without anxious distressBaseline19815.0 ± 5.1–––Week 121619.5 ± 5.7161−5.7 ± 5.7<0.001GAD-7 total scoreOverallBaseline38110.4 ± 5.1–––Week 123155.8 ± 5.0315−4.5 ± 5.5<0.001With anxious distressBaseline18311.6 ± 4.8–––Week 121546.1 ± 5.0154−5.3 ± 5.8<0.001Without anxious distressBaseline1989.2 ± 5.0–––Week 121615.6 ± 4.9161−3.7 ± 5.2<0.001SDS total scoreOverallBaseline37217.7 ± 7.5–––Week 1231511.3 ± 8.7309−6.5 ± 9.3<0.001With anxious distressBaseline18118.3 ± 7.6–––Week 1215411.8 ± 8.8152−6.2 ± 9.2<0.001Without anxious distressBaseline19117.1 ± 7.4–––Week 1216110.9 ± 8.6157−6.7 ± 9.6<0.001EQ-5D-5L QOL scoreOverallBaseline3810.62 ± 0.18–––Week 123140.74 ± 0.193140.11 ± 0.19<0.001With anxious distressBaseline1830.61 ± 0.18–––Week 121540.74 ± 0.201540.13 ± 0.19<0.001Without anxious distressBaseline1980.64 ± 0.18–––Week 121600.74 ± 0.181600.10 ± 0.18<0.001PDQ-D-5 total scoreOverallBaseline37914.1 ± 5.0–––Week 1231311.5 ± 5.1312−2.9 ± 4.7<0.001With anxious distressBaseline18314.6 ± 5.3–––Week 1215411.8 ± 5.2154−2.9 ± 4.6<0.001Without anxious distressBaseline19613.7 ± 4.7–––Week 1215911.3 ± 5.0158−2.8 ± 4.8<0.001Notes: Analyses were based on the full analysis set. P-values of the change from baseline were calculated using the paired t test.Abbreviations: EQ-5D-5L, EuroQol 5 dimensions 5-level; GAD-7, Generalized Anxiety Disorder 7-item; n, number of subjects within each category; PDQ-D-5, Perceived Deficits Questionnaire for Depression 5-item; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; QOL, quality of life; SD; standard deviation; SDS, Sheehan Disability Scale. Changes from Baseline in Patient-Reported Outcomes at Baseline and Week 12 Notes: Analyses were based on the full analysis set. P-values of the change from baseline were calculated using the paired t test. Abbreviations: EQ-5D-5L, EuroQol 5 dimensions 5-level; GAD-7, Generalized Anxiety Disorder 7-item; n, number of subjects within each category; PDQ-D-5, Perceived Deficits Questionnaire for Depression 5-item; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; QOL, quality of life; SD; standard deviation; SDS, Sheehan Disability Scale. Similar patterns of improvement were observed in both patients with and without anxious distress across multiple symptoms and functional domains. Response and Remission MADRS response and remission rates increased over time in the overall population (Table 4). At week 12, more than one-third of patients achieved response and remission, both among those with anxious distress (44.3% for response rate and 32.8% for remission rate) and those without anxious distress (41.9% for response rate and 39.4% for remission rate).Table 4Response and Remission Rate Over TimeWeek 4Week 8Week 12Response ratean (%)n (%)n (%)Overall(N=381)71 (18.6)134 (35.2)164 (43.0)With anxious distress(N=183)37 (20.2)65 (35.5)81 (44.3)Without anxious distress(N=198)34 (17.2)69 (34.8)83 (41.9)Remission ratebn (%)n (%)n (%)Overall(N=381)41 (10.8)99 (26.0)138 (36.2)With anxious distress(N=183)19 (10.4)49 (26.8)60 (32.8)Without anxious distress(N=198)22 (11.1)50 (25.3)78 (39.4)Notes: N denotes the number of patients in the full analysis set in each group. a Resulted in ≥50% reduction from baseline in the MADRS total score. b For patients with the MADRS total score >10 at baseline, resulted in ≤10.Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; n, number of subjects within each category. Table 4Response and Remission Rate Over TimeWeek 4Week 8Week 12Response ratean (%)n (%)n (%)Overall(N=381)71 (18.6)134 (35.2)164 (43.0)With anxious distress(N=183)37 (20.2)65 (35.5)81 (44.3)Without anxious distress(N=198)34 (17.2)69 (34.8)83 (41.9)Remission ratebn (%)n (%)n (%)Overall(N=381)41 (10.8)99 (26.0)138 (36.2)With anxious distress(N=183)19 (10.4)49 (26.8)60 (32.8)Without anxious distress(N=198)22 (11.1)50 (25.3)78 (39.4)Notes: N denotes the number of patients in the full analysis set in each group. a Resulted in ≥50% reduction from baseline in the MADRS total score. b For patients with the MADRS total score >10 at baseline, resulted in ≤10.Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; n, number of subjects within each category. Response and Remission Rate Over Time Notes: N denotes the number of patients in the full analysis set in each group. a Resulted in ≥50% reduction from baseline in the MADRS total score. b For patients with the MADRS total score >10 at baseline, resulted in ≤10. Abbreviations: MADRS, Montgomery-Åsberg Depression Rating Scale; n, number of subjects within each category. Safety The incidence of TEAEs is summarized in Table 5. Overall, TEAEs were reported in approximately one-third of patients. The most commonly reported events (>2.0%) were nausea, somnolence, dizziness, headache, and nasopharyngitis. Serious TEAEs were infrequent (1.5%). No deaths related to treatment were reported.Table 5Overall Incidence of TEAEsAdverse Event TypeOverall (N=407) n (%)With Anxious Distress (N=198) n (%)Without Anxious Distress (N=209) n (%)TEAEs138 (33.9)66 (33.3)72 (34.4) Drug-related TEAEs96 (23.6)51 (25.8)45 (21.5)Serious TEAEs6 (1.5)4 (2.0)2 (1.0) Drug-related serious TEAEs1 (0.2)01 (0.5)TEAEs leading to drug discontinuation37 (9.1)22 (11.1)15 (7.2) Drug-related TEAEs leading to drug discontinuation33 (8.1)20 (10.1)13 (6.2) Serious TEAEs leading to drug discontinuation4 (1.0)2 (1.0)2 (1.0) Drug-related serious TEAEs leading to drug discontinuation1 (0.2)01 (0.5)Serious TEAEs leading to death1 (0.2)1 (0.5)0 Drug-related serious TEAEs leading to death000Most common TEAEs (with ≥ 2% in any group) Nausea40 (9.8)16 (8.1)24 (11.5) Somnolence21 (5.2)11 (5.6)10 (4.8) Dizziness13 (3.2)4 (2.0)9 (4.3) Headache11 (2.7)7 (3.5)4 (1.9) Nasopharyngitis11 (2.7)4 (2.0)7 (3.3) Malaise8 (2.0)1 (0.5)7 (3.3) Constipation7 (1.7)4 (2.0)3 (1.4) Insomnia6 (1.5)4 (2.0)2 (1.0)Notes: Percentages (%) are based on the number of patients in the safety analysis set in each group (N). Number of patients with at least one event is summarized for each type of event.Abbreviations: n, number of subjects within each category; TEAE, treatment-emergent adverse event. Table 5Overall Incidence of TEAEsAdverse Event TypeOverall (N=407) n (%)With Anxious Distress (N=198) n (%)Without Anxious Distress (N=209) n (%)TEAEs138 (33.9)66 (33.3)72 (34.4) Drug-related TEAEs96 (23.6)51 (25.8)45 (21.5)Serious TEAEs6 (1.5)4 (2.0)2 (1.0) Drug-related serious TEAEs1 (0.2)01 (0.5)TEAEs leading to drug discontinuation37 (9.1)22 (11.1)15 (7.2) Drug-related TEAEs leading to drug discontinuation33 (8.1)20 (10.1)13 (6.2) Serious TEAEs leading to drug discontinuation4 (1.0)2 (1.0)2 (1.0) Drug-related serious TEAEs leading to drug discontinuation1 (0.2)01 (0.5)Serious TEAEs leading to death1 (0.2)1 (0.5)0 Drug-related serious TEAEs leading to death000Most common TEAEs (with ≥ 2% in any group) Nausea40 (9.8)16 (8.1)24 (11.5) Somnolence21 (5.2)11 (5.6)10 (4.8) Dizziness13 (3.2)4 (2.0)9 (4.3) Headache11 (2.7)7 (3.5)4 (1.9) Nasopharyngitis11 (2.7)4 (2.0)7 (3.3) Malaise8 (2.0)1 (0.5)7 (3.3) Constipation7 (1.7)4 (2.0)3 (1.4) Insomnia6 (1.5)4 (2.0)2 (1.0)Notes: Percentages (%) are based on the number of patients in the safety analysis set in each group (N). Number of patients with at least one event is summarized for each type of event.Abbreviations: n, number of subjects within each category; TEAE, treatment-emergent adverse event. Overall Incidence of TEAEs Notes: Percentages (%) are based on the number of patients in the safety analysis set in each group (N). Number of patients with at least one event is summarized for each type of event. Abbreviations: n, number of subjects within each category; TEAE, treatment-emergent adverse event. The incidence and patterns of TEAEs were summarized descriptively for patients with and without anxious distress. Although drug‑related TEAEs (25.8% in patients with anxious distress and 21.5% in those without) and discontinuations due to drug‑related TEAEs (10.1% and 6.2%, respectively) were numerically more common in patients with anxious distress, no formal statistical comparisons were performed and these findings should be interpreted descriptively. One death due to suicide occurred in a patient with anxious distress and was assessed by the investigator as unrelated to venlafaxine. Discussion The present prospective observational study evaluated the effectiveness and safety of venlafaxine in Japanese patients with MDD and provided insight into how the presence of DSM-5 anxious distress may influence treatment response in routine clinical practice. In both patients with and without anxious distress, venlafaxine treatment was associated with improvements in depressive symptoms as well as in anxiety symptoms, functional impairment, health-related QOL, and perceived cognitive deficits over the 12-week observation period. These findings highlight the multi-dimensional impact of treatment in a real-world setting, where patients often present with complex and heterogeneous symptom profiles. In line with previous reports using the DSM-5 anxious distress specifier,7,8,13 patients with anxious distress accounted for nearly half of the study population and exhibited greater baseline symptom severity across multiple domains, including depressive symptoms (MADRS) and anxiety-related measures (GAD-7). Bartoli et al did not find a clear association between anxious distress and depressive symptom severity in an inpatient sample;29 this discrepancy may be attributable to differences in study populations (eg, inpatient vs outpatient settings) or overall illness severity. Our baseline findings regarding socio-demographic characteristics were that patients with anxious distress were younger and less likely to live with cohabitants than those without anxious distress. Otsubo et al also observed that DSM-5 anxious distress was associated with younger age, unmarried status, and living alone among Japanese patients with MDD in the continuation/maintenance phase.13 Following venlafaxine treatment, substantial improvements in MADRS total score were observed in both patients with and without anxious distress. These results in the full analysis set were also similar to those observed in the per-protocol set and the exploratory analysis set (Table S3 in the Supplementary Materials). This suggests that patients may experience clinical improvements during venlafaxine treatment even for patients with MDD who present with prominent anxiety symptoms, a population often considered more challenging to treat in routine clinical practice. When considering response and remission outcomes, our results showed broadly similar response rates between subgroups but patients with anxious distress had lower remission rates. Because the study was not designed with the primary objective of comparing outcomes between patients with and without anxious distress, these findings should be interpreted descriptively, and no definitive conclusions regarding differences or similarities in treatment response between subgroups can be drawn. Regarding previous studies using HAM-D anxiety subgroups, a pooled analysis of venlafaxine trials has shown that patients with higher baseline anxiety exhibited greater reductions in MADRS total score after venlafaxine treatment and had higher remission rate compared with those with lower anxiety,30 indicating that venlafaxine remains effective in reducing depressive symptoms in patients with substantial anxiety. With respect to studies employing the DSM-5 anxious distress specifier, direct evidence regarding antidepressant treatment outcomes assessed by MADRS remains limited. Most available studies have primarily focused on baseline characteristics or longitudinal prognosis rather than short-term treatment response. In this context, our findings extend the existing literature by showing that improvements in MADRS scores were observed after 12 weeks of venlafaxine treatment in both patients with and without anxious distress, despite higher baseline severity observed among patients with anxious distress, as reflected by MADRS and GAD-7 scores. A notable strength of the present study is the comprehensive assessment of patient-reported outcomes. Improvements were observed across measures of depressive symptoms, anxiety, functional disability, QOL, and cognitive complaints in both subgroups. This broad pattern of improvement is particularly relevant for patients with anxious distress, whose symptom burden often extends beyond core depressive symptoms and may not be fully captured by clinician-rated depression severity scales alone. The alignment of clinician-rated and patient-reported outcomes enhances the clinical interpretability of the findings and underscores the value of multidimensional outcome assessment in real-world studies. Efficacy analyses were also conducted in the exploratory analysis set, which included patients who received venlafaxine according to the prespecified dosing and titration schedule described in the package insert.31 The results for all primary and secondary efficacy endpoints (Tables S4–S7 and Figure S1 in the Supplementary Materials) were consistent with those observed in the full analysis set, providing supportive descriptive evidence across analytical populations. Given the observational and single-arm design, the present findings should not be interpreted as demonstrating a causal effect of venlafaxine or as establishing differences between subgroups. Rather, improvements in symptomatic and functional outcomes were observed during venlafaxine treatment in routine clinical conditions. Interpretation of these observations requires caution, as the findings are exploratory and intended to inform expected treatment patterns rather than to establish definitive effectiveness. From a safety perspective, venlafaxine was generally well tolerated, and the observed adverse event profile was in line with its established safety profile. No unexpected safety findings were identified. Drug-related adverse events and adverse events leading to treatment discontinuation were numerically more frequent among patients with anxious distress. Although no formal statistical comparisons between subgroups were performed, these findings were broadly aligned with previous studies, such as STAR*D study, suggesting that patients with “anxious depression” assessed by the HAM-D may experience a higher burden of adverse events and lower treatment tolerability during antidepressant therapy.5,6 In addition, a cross-sectional study focusing on DSM-5 anxious distress has suggested that anxious distress population may be characterized by greater clinical severity,11 which may contribute to increased vulnerability to treatment-related adverse events. One death due to suicide occurred in a patient with anxious distress and was assessed by the investigator as unrelated to venlafaxine. The patient was a woman aged ≥60 years with mild anxious distress, who had comorbid non-malignant gastrointestinal conditions and lower back pain. She was receiving venlafaxine at a stable dose of 150 mg/day after the titration schedule described in the package insert and died by suicide on day 61 after treatment initiation. No other adverse events or clinical deterioration were reported prior to the event. Although patients considered to be at high or imminent risk of suicide were excluded at baseline, this case highlights the inherent and unpredictable risk of suicidality in patients with MDD. Given that anxious distress is associated with greater clinical severity and may be linked to an increased risk of suicidality, this event should be interpreted with caution. Interpretation of this outcome should also consider the lack of a clear temporal pattern of symptom worsening before the event and the investigator’s assessment that the event was not treatment-related. Limitations Several limitations should be considered when interpreting the results of this study. As this was a single-arm observational study without a control group, causal inferences regarding the effectiveness of venlafaxine cannot be established. All analyses were descriptive in nature; therefore, differences in treatment response between subgroups cannot be determined. In addition, anxious distress was dichotomized as present or absent in the primary analyses. DSM-5 defines multiple levels of anxious distress severity (mild, moderate, and moderate to severe or more), and thus this binary classification may have obscured potential dose–response relationships between anxious distress severity and treatment outcomes. Although severity-based exploratory analyses could provide additional insights, such analyses were not performed in the present study. Consequently, the findings should be interpreted as exploratory and hypothesis-generating rather than confirmatory. Although standardized procedures for MADRS assessments were implemented, no formal measures were taken to assess or control for inter-rater variability. Therefore, variability in the assessment of primary endpoint across sites cannot be excluded. Patients considered to be at risk of imminent suicide were excluded at the discretion of investigating psychiatrists with appropriate clinical experience. This may limit the generalizability of the findings, as suicidality is an important clinical feature of MDD. Despite this exclusion criterion, a suicide occurred in a patient with anxious distress during the study. Detailed evaluation of changes in suicidality during follow-up was not systematically performed, and therefore the relationship between treatment, anxious distress status, and suicide risk cannot be fully characterized. Treatment decisions, including dose titration and concomitant therapies, were made according to routine clinical practice and could not be fully controlled. The relatively short follow-up period of 12 weeks also limits the assessment of long-term outcomes. Furthermore, as this is an observational study, the results may be subject to confounding by indication, comorbid anxiety disorders, and other uncontrolled factors. Because analyses were based on observed cases without imputation, potential bias due to missing data cannot be excluded. In antidepressant studies, treatment discontinuation and missing data may be associated with multiple factors, including treatment efficacy, tolerability, clinical worsening, early improvement, or baseline characteristics such as anxious distress status. In this study, a proportion of patients discontinued treatment before week 12, with adverse events being a most common reason. However, no formal comparison of baseline characteristics between completers and non-completers was conducted, and no sensitivity analyses (eg, imputation-based approaches) were performed. Therefore, the potential impact of attrition bias on the observed treatment outcomes cannot be ruled out, and the findings should be interpreted with caution. Despite these limitations, the present study provides valuable real-world evidence regarding the use of venlafaxine in Japanese patients with MDD, including those with anxious distress. By reflecting routine prescribing patterns and capturing a wide range of clinically relevant outcomes, this study offers insights that are directly applicable to everyday clinical decision-making. Conclusion Venlafaxine treatment was associated with improvements across multiple symptoms and functioning domains in Japanese patients with MDD. Improvements were seen in patients with and without DSM-5 anxious distress. The observed safety profile was in line with established findings. These results provide descriptive real-world evidence on treatment outcomes with venlafaxine in routine psychiatric practice. However, interpretation should be cautious, as the study design does not allow causal inference or formal comparisons between subgroups. These findings may inform clinical decision-making in patients with complex and heterogeneous presentations.